Results 201 to 210 of about 1,959,228 (334)

A Microfluidic Device Integrating a Glucose Sensor and Calibration Function for Cell-Based Assays. [PDF]

Biosensors (Basel)
Chen L, Shinha K, Nakamura H, Komori K, Kimura H.   +4 more
europepmc   +1 more source

Vascular and Blood Compatibility of Engineered Cationic Cellulose Nanocrystals in Cell-Based Assays. [PDF]

Nanomaterials (Basel), 2021
Bernier A, Tobias T, Nguyen H, Kumar S, Tuga B, Imtiaz Y, Smith CW, Sunasee R, Ckless K.   +8 more
europepmc   +1 more source

Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay [PDF]

, 2018
Ruby Cheung, Gregory W. deHart, Lynne Jesaitis, Stephen J. Zoog, Andrew C. Melton   +4 more
openalex   +1 more source

Biocompatibility of Silicate Based Root Canal Sealers on Human Fibroblast Cells-In Vitro Study based on Cell Viability Assay

, 2023
Aswiyaa Muhamed Ilyas
openalex   +1 more source

PYCR1 inhibition in bone marrow stromal cells enhances bortezomib sensitivity in multiple myeloma cells by altering their metabolism

Molecular Oncology, EarlyView.
This study investigated how PYCR1 inhibition in bone marrow stromal cells (BMSCs) indirectly affects multiple myeloma (MM) cell metabolism and viability. Culturing MM cells in conditioned medium from PYCR1‐silenced BMSCs impaired oxidative phosphorylation and increased sensitivity to bortezomib.
Inge Oudaert, Lauren van den Broecke, Osman Aksoy, Judith Lind, Sonia Vallet, Arne Van der Vreken, Gamze Ates, Ann Massie, Ken Maes, Kim De Veirman, Elke De Bruyne, Karin Vanderkerken, Klaus Podar, Eline Menu   +13 more
wiley   +1 more source

JCV-specific cell-based assays for PML risk assessment in lupus and multiple sclerosis patients with and without natalizumab. [PDF]

Front Neurol
Wu Q, Mills EA, Wang Q, Mao G, Mao-Draayer Y.   +4 more
europepmc   +1 more source

Phytochemical Profile and Chemopreventive Properties of Cooked Glutinous Purple Rice Extracts Using Cell-Based Assays and Rat Model. [PDF]

Foods, 2022
Guo H, Chariyakornkul A, Phannasorn W, Mahatheeranont S, Wongpoomchai R.   +4 more
europepmc   +1 more source

In vitro properties of patient serum predict clinical outcome after high dose rate brachytherapy of hepatocellular carcinoma

Molecular Oncology, EarlyView.
Following high dose rate brachytherapy (HDR‐BT) for hepatocellular carcinoma (HCC), patients were classified as responders and nonresponders. Post‐therapy serum induced increased BrdU incorporation and Cyclin E expression of Huh7 and HepG2 cells in nonresponders, but decreased levels in responders.
Lukas Salvermoser, Jan Niklas Schäfer, Shraga Nahum Goldberg, Philipp Maximilian Kazmierczak, Moritz Nikolaus Gröper, Philipp Franz Linden, Elif Öcal, Tanja Burkard, Stefanie Corradini, Najib Ben Khaled, Moritz Wildgruber, Max Seidensticker, Jens Ricke, Matthias Stechele, Marianna Alunni‐Fabbroni   +14 more
wiley   +1 more source

Efficiency of cell-based assays in detecting AChR antibodies in myasthenia gravis sera with low antibody concentrations as determined by radioimmunoprecipitation assay. [PDF]

Front Immunol
Tzartos JS, Vakrakou AG, Karagiorgou K, Zouvelou V, Chroni E, Damato V, Beretta F, Salakou S, Sfyroera E, Veltsista D, Voumvourakis K, Giannopoulos S, Tsivgoulis G, Tzartos S.   +13 more
europepmc   +1 more source

Discovering cell-active BCL6 inhibitors: effectively combining biochemical HTS with multiple biophysical techniques, X-ray crystallography and cell-based assays. [PDF]

Sci Rep, 2022
Pierrat OA, Liu M, Collie GW, Shetty K, Rodrigues MJ, Le Bihan YV, Gunnell EA, McAndrew PC, Stubbs M, Rowlands MG, Yahya N, Shehu E, Talbot R, Pickard L, Bellenie BR, Cheung KJ, Drouin L, Innocenti P, Woodward H, Davis OA, Lloyd MG, Varela A, Huckvale R, Broccatelli F, Carter M, Galiwango D, Hayes A, Raynaud FI, Bryant C, Whittaker S, Rossanese OW, Hoelder S, Burke R, van Montfort RLM.   +33 more
europepmc   +1 more source